Rapid Micro Biosystems Q1 Revenue Up 11% to $8M, Reaffirms $37M-$41M Guidance
Rapid Micro Biosystems reported Q1 2026 revenue of $8.0 million, up 11.1% year-over-year, with product revenue rising 36% and recurring revenue climbing 27.7%. The company placed six Growth Direct systems versus three a year earlier, reaffirmed full-year revenue guidance of $37.0 million to $41.0 million and executed a strategic services agreement with MilliporeSigma.
1. Q1 2026 Financial Performance
Total revenue reached $8.0 million in the first quarter of 2026, an 11.1% increase from $7.2 million a year earlier. Product revenue climbed 36% to $5.6 million, recurring revenue rose 27.7% to $5.1 million, while service revenue declined 21.9% to $2.4 million. Gross margin was 4.6% and net loss totaled $14.3 million.
2. Growth Direct System Placements and Collaboration
The company placed six Growth Direct systems during Q1 2026, up from three placements in Q1 2025, and completed validation of five customer systems. It advanced a strategic collaboration with MilliporeSigma by executing a services agreement to support enterprise-level deployments of its automation solutions.
3. 2026 Outlook and Guidance
Rapid Micro Biosystems reaffirmed its full-year 2026 revenue guidance of $37.0 million to $41.0 million, targeting 30 to 38 Growth Direct system placements and at least 25 system validations. The company expects to achieve a full-year gross margin of approximately 20%, with a Q4 exit rate in the mid-20% range.